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’INTRODUCTION
The secreted glycoprotein autotaxin (ATX) is a phosphodies-
terase responsible for the hydrolysis of lysophosphatidylcholine
(LPC)intolysophosphatidicacid(LPA)andcholine,asdepicted
in Scheme 1.
1,2 The bioactive lipid LPA stimulates migration,
proliferationandsurvivalofcells byactivatingspeciﬁcGprotein-
coupled receptors.
3 The ATX-LPA signaling axis is involved in
cancer, inﬂammation and ﬁbrotic disease.
4 6 Potent and selec-
tive ATX inhibitors are needed to elucidate the contribution of
ATXactiontosignalingcascadesthatmayresultindiseaseincase
of malfunction.
ATX, also known as eNPP2, is a unique member of the ecto-
nucleotide pyrophosphatase/phosphodiesterase (eNPP) family
of proteins. It is the only family member capable of producing
LPA by hydrolysis of LPC.
7 Recently reported crystal structures
of mouse
8 and rat
9 ATX conﬁrmed that a threonine residue and
two zinc ions are necessary for activity of ATX.
10 From these
structures, it could be concluded that ATX hydrolyzes its sub-
stratesthroughatypicalalkalinephosphatase/phosphodiesterase
mechanism.
11,12Furthermore,thesestructuresshowedthatATX
speciﬁcally binds its lipid substrates in a hydrophobic pocket
extending from the active site of ATX. This pocket accommo-
dates the alkyl chain of the lipids in diﬀerent poses as was also
shown in various crystal structures.
8
Recently, we described the discovery of a boronic acid-based
ATX inhibitors that helped to reveal the short half-life (∼5 min)
of LPA in vivo.
13,14 We introduced a boronic acid moiety in the
inhibitor structure to rationally target the threonine oxygen
nucleophile ofATXwithahardmatching Lewis acid. Thecrystal
structure of ATX in complex with HA155 (1)
9 conﬁrmed our
hypothesis that this inhibitor targets the threonine oxygen
nucleophile in the ATX active site via the boronic acid moiety,
while the hydrophobic 4-ﬂuorobenzyl moiety of inhibitor 1
targets the hydrophobic pocket responsible for lipid binding
(Figure 1).
Here, we report a number of synthetic routes, systematically
substituting linkers and the thiazolidine-2,4-dione core in 1,w h i l e
keeping the boronic acid moiety untouched. The observed structure 
activityrelationscouldwellbeexplainedfromtheATXstructurein
complex with inhibitor 1. A remarkable binding pose of a novel
inhibitor, as predicted from molecular docking experiments,
suggests additional avenues for further inhibitor design.
’RESULTS AND DISCUSSION
Design of Inhibitors. The structure of inhibitor 1 bound to
the ATX active site (Figure 1) showed that its 4-fluorobenzyl
moiety binds into the hydrophobic lipid binding pocket of ATX
(Figure 1C,D).
9 This pocket also accommodates the lipid tail of
LPA,thehydrolysisproductofLPC.
8Thethiazolidine-2,4-dione
core of 1 and the conjugated aromatic ring are located between
the hydrophobic pocket and the catalytic site (Figure 1D). The
etherlinker,bridgingthetwoaromaticringsin1,andespeciallya
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methylene and arylboronic acid moiety are well accessible to
solvent(Figure1C).Bindingofinhibitor1totheATXactivesite
is predominately driven by hydrophobic interactions (the inter-
action interface is approximately 500 Å
2) and by the boronic
acid binding to the threonine oxygen nucleophile of ATX.
9 The
boron oxygen distance observed is ∼1.6 Å, which is consistent
with a covalent bond. As expected, this binding is reversible
evidencedbythefactthatATXactivitycanbefullyrestoredupon
washing out the inhibitor.
13 In addition, one of the boronic acid
hydroxyl moieties is tethered by the two zinc ions in the ATX
active site. Thus, the boronic acid moiety targets not only the
threonine oxygen nucleophile, but also the two zinc ions that are
essential for catalytic activity of ATX (Figure 1B). Remarkably,
there are no hydrogen bonds or salt bridges that participate in
bindingofinhibitor1toATX.Inhibitor1islockedinaposewith
reducedmolecularflexibility,forminganidealstartingpointfora
structure-based approach to further modifications.
Previously, we determined that the 4-ﬂuorobenzyl moiety is
preferred from over 40 benzylic substituents tested.
13 For this
reason,weleftthe4-ﬂuorobenzylmoietyuntouchedinthisstudy.
We investigated new design options, starting by modifying the
ether linker ininhibitor 1. Wedecidedtoreplacethe etherlinkage
(OCH2) with various amides, an amine, and an E-conﬁgured
double bond (CONH (17), CONCH2 (18), NHCO (19),
NHCH2 (36), and (E)-CHdCH (20); see Table 1). The
thiazolidine-2,4-dionecorewasinvestigatednext.Wesubstituted
the sulfur atom present with (substituted) amino and methylene
moieties (NH (26), NCH3 (28), or CH2 (32)) (Table 2). The
carbon double bond conjugated to the thiazolidine-2,4-dione
carbonyl moiety forms a possible Michael acceptor. Although
this Michael acceptor is resistant to nucleophilic additions in
vitro(SupportingInformationFigureS1)itmaybeabiologically
activeMichaelacceptor invivo,andtherefore, we investigatedits
removal.
Chemical Synthesis of Modified Inhibitors. We first ex-
plored synthetic routes to replace the ether linkage in 1. The
synthesis of target molecules 17 20 (Scheme 2) starts with
palladium catalyzed borylation of appropriate aldehydes via a
Scheme 1. Autotaxin (ATX) is Responsible for Hydrolyzing the Lipid Lysophosphatidylcholine (LPC) into Lysophosphatidic
Acid (LPA) and Choline
Figure 1. ATX structure liganded with inhibitor 1 (PDB ID 2XRG).
(A) Surface representation of ATX with inhibitor 1 (magenta). (B)
Binding of inhibitor 1 to the threonine oxygen nucleophile and two zinc
ions. (C) Visualizing the ether linker of inhibitor 1 bound to ATX. (D)
Visualizing the degree of freedom for the thiazolidine-2,4-dione core of
inhibitor 1 in the ATX binding site.
Table 1. IC50 Values of the Inhibitors Resulting from the
Linker Modiﬁcation
aIC50 values have been determined in the choline release assay using
40 μM LPC and 10 nM ATX. The dose response curve of inhibitor 17
shows biphasic curve (see Supporting Information Figure S2).4621 dx.doi.org/10.1021/jm200310q |J. Med. Chem. 2011, 54, 4619–4626
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Suzuki-Miyaura reaction
15 as depicted in Scheme 2 (for synth-
eses of aldehydes 2 6 see Supporting Information). This
reaction smoothly provided intermediates 7 11. Next, the
pinacolprotectinggroupwashydrolyzedunderacidicconditions
and oxidatively destroyed by NaIO4 giving boronic acid alde-
hydes 12 16. In the final step 3-(4-fluorobenzyl)thiazolidine-
2,4-dione is reacted with the boronic acid aldehyde by Knoevenagel
condensationtoselectively givethe Z-isomerofthe final products
(1 and 17 20).
In order to remove the potential Michael acceptor present,
we reduced the double bond in inhibitor 1 using hydrogen and
palladium on carbon (Scheme 3A), to give compound 21.T o
reduce the carbonyl moiety also in the thiazolidine-2,4-dione
core of 1, we used NaBH4 resulting in hemiaminal 22. After
addition of sulfuric acid to the reaction mixture to eliminate the
hydroxyl moiety in 22, unsaturated inhibitor 23 was obtained.
For the syntheses of imidazolidine-2,4-dione-based inhibitors
26 and 28, imidazolidine-2,4-dione (24) was mono N-alkylated
with4-ﬂuorobenzylbromidetogiveintermediate25(Scheme3B).
Reactionof25byaKnoevenagelcondensation withaldehyde12
selectively resulted in the formation of the Z-isomer of 26.I n
parallel, intermediate 25 was methylated to give compound 27.
Finally, 27 was condensed with aldehyde 12 resulting in target
molecule 28. Both the Z- and E-isomers were formed in a 1:4
(Z:E) ratio. To obtain and isolate solely the Z-isomer 28,w e
N-methylated compound 26.
Core-hopping from thiazolidine-2,4-dione to pyrrolidine-2,5-
dione is depicted in Scheme 3C. The route starts with the forma-
tionofaWittigreagentstartingfrom2,5-pyrroledione(29),which
is reacted with triphenylphosphine to form ylide 30.
16 The Wittig
reaction of the carbonyl stabilized ylide 30 with aldehyde 12 selec-
tivelyleads to theE-isomerofintermediate31asexpected. Finally,
compound31isN-alkylatedwith4-ﬂuorobenzylbromideresulting
in the pyrrolidine-2,5-dione product 32.
For the synthesis of a ﬁnal tetrahydroisoquinoline-based core
with a more rigid structure, the secondary amine in R-o rS-
tetrahydroisoquinoline 33 is reacted with 4-ﬂuorobenzyl isocya-
nate in the presence of sodium hydroxide to form a urea inter-
mediate. The imidazolidine ring is then formed upon acidiﬁca-
tionwithhydrochloricacid,resultingincompoundR-orS-34.In
theﬁnalstep,intermediate34isO-alkylatedwith4-(bromomethyl)-
phenylboronic acid resulting in R-o rS-35.
Structure Activity Relations of Inhibitors and Autotaxin.
Activity of the new molecules resulting from the linker and core
modifications were determined in an LPC hydrolysis assay
described previously,
13,17 in which ATX-mediated release of
choline from LPC is detected by a two-step enzymatic colori-
metric reaction. The IC50 values observed for inhibitors with
modified linkers and cores are listed in Tables 1 and 2.
Whenwereplacedtheethermoiety(OCH2,inhibitor1,IC 50=
5.7 nM) for an amide linker (CONH, 17), we observed a signi-
ﬁcantloss of activity (IC50 = 147 nM). The dose response curve
of inhibitor 17 shows a biphasic curve
18 that could suggest several
binding sites of this inhibitor for ATX (Supporting Information
Figure S2). Expanding the CONH linker (17) to a more ﬂexible
CONHCH2 linker (18) improved the IC50 value (71 nM) by
2-fold compared to inhibitor 17. Reversing the amide linker in 17
to yield compound 19, results in high potency (IC50 =1 0n M ) ,
similar to inhibitor 1. However, inhibitor 19 is not able to achieve
full inhibition, and 10% residual ATX activity is observed (Sup-
porting Information Figure S3). Apparently, a more rigid amide
linkerresultsinsuboptimalbindingoftheinhibitor.Therefore,we
synthesizedthemoreﬂexibleamineanalogue36(forthesynthesis
of inhibitor 36 see Supporting Information). This resulted indeed
inapotentinhibitor(IC50=8.3nM),similarto1,andwithnore-
sidual ATX activity (Supporting Information Figure S3). Intro-
duction of an (E)-CHdCH linker resulted in compound 20,
which was inactive in the nanomolar range (IC50 >5μM). This
observation can be explained by the fact that the two aromatic
rings linked with a ﬂexible OCH2 linker in inhibitor 1 are posi-
tioned in an angle of roughly 90 in the ATX structure (see
Figure 1B) which cannot be achieved by the (E)-CHdCH linker
due to its rigid planar conformation.
Table 2. IC50 Values of the Inhibitors Resulting from the
Core Modiﬁcation
aIC50 values have been determined in the choline release assay using
40 μM LPC and 10 nM ATX. E-28 contains 20% of the Z-isomer.4622 dx.doi.org/10.1021/jm200310q |J. Med. Chem. 2011, 54, 4619–4626
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Next, we explored the activity of compounds with a modiﬁed
core. Reducing the carbon double bond in 1resulted in little loss
of activity in 21 with an IC50 value of 25 nM. Thus, although
rigidity is preferred, the Michael acceptor can easily be removed
without signiﬁcant loss in activity. Reducing both the carbon
double bond and the neighboring carbonyl in inhibitor 1 to
hemiaminal 22, led to a signiﬁcant loss in potency (IC50 =
1.6 μM). Inhibitor 23, where the hydroxyl moiety in compound
22 is removed is not very potent either (IC50 = 683 nM),
indicates that the carbonyl moiety is important for binding. It
appears from the crystal structure of inhibitor 1 bound to ATX
thatπ-stackingbetweenthephenylringofphenylalanineresidue
274 (F274) and the carbonyl moiety in 1 is very likely seen their
distance (4.1 Å, Supporting Information Figure S4).
19 By remo-
ving the carbonyl moiety in 1 or by changing it into a hydroxyl
moiety, π-stacking will be lost resulting in lower potencies as
observed for inhibitor 22 and 23.
The sulfur heteroatom in the thiazolidine-2,4-dione core was
replacedwithotheratomsandmoieties.Westartedbyreplacingthe
sulfur atom in 1 with a methylene moiety gives compound 32 with
an IC50 v a l u eo f7 . 3n M ,c o m p a r a b l et oi n h i b i t o r1. Replacement of
the sulfur atom for an amino group (26,I C 50 =2 6n M )r e s u l t e di n
little loss in activity compared to inhibitor 1.W h e nt h ea m i n ei n
compound 26 is methylated, potency for the resulting inhibitor
Z-28 (IC50 = 6.7 nM) is slightly increased. Interestingly, the
E-isomer of 28 (IC50 = 5.3 nM) is marginally more potent than
Z-28 or inhibitor 1,aﬁnding that we did not anticipate.
IntriguedbythecharacteristicsofinhibitorsZ-28andE-28,we
decided to calculate likely binding poses. For this purpose, we
used the Glide docking software.
20 22 To validate our docking
approach where we constrain the boronic acid moiety, we ﬁrst
docked inhibitor 1 back into the ATX active site, resulting in a
pose (Figure 2B) very similar to the original crystal structure
(Figure 2A) with a rmsd value of 1.1 Å (for superimposed image
see Supporting Information Figure S5). Next, we docked the Z-
and E-isomers of inhibitor 28 (the three best docking poses are
depicted in Figure 2C and D). The docking poses of Z-28
correspond to the pose of inhibitor 1 in the ATX structure.
However, two of the best three docking poses for E-28 suggest
that the 4-ﬂuorobenzyl moiety likely binds to a diﬀerent area in
the hydrophobic pocket (Figure 2D). The imidazolidine-2,
4-dione core of E-28 is ﬂipped around the double bond axis in
the ATX binding site compared to its Z-isomer (compare
Figure 2C with D). This observation is in agreement with the
conformations of both isomers. In addition, the binding poses of
Z-28 and E-28 resulting from our docking study suggest that the
current 4-ﬂuorobenzyl moiety could be expanded from the
methylene moiety in the 4-ﬂuorobenzyl substituent with other
substituents in future ATX inhibitors.
Finally, we evaluated inhibitors in which we introduced a
rigidiﬁed three-ring system (Table 2) incorporating a tetrahydro-
isoquinoline motif that we deemed likely to bind. This modiﬁca-
tion avoids the presence of a Michael acceptor, while introducing
rigidityandanewcorestructure.Thismodiﬁcationresultedinthe
Scheme 2. Synthetic Route Towards Linker Modiﬁed Inhibitors
Scheme 3. Synthetic Routes Towards Core Modiﬁed Inhibitors4623 dx.doi.org/10.1021/jm200310q |J. Med. Chem. 2011, 54, 4619–4626
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chiralinhibitor35,whichisstillverypotentalthoughsomeactivity
is lost compared to 1.N os i g n i ﬁcant diﬀerence is observed in
potencyforeithertheSorRenantiomersofinhibitor35,withIC 50
values of 55 and 59 nM, respectively.
Insummary,weexploredstructure activityrelationsbuildingon
boronic acid-based ATX inhibitor 1, which resulted in a number of
potent inhibitors. We used the crystal structure of ATX liganded
with inhibitor 1
9 to explain the structure activity relationships
observed for a rational inhibitor modiﬁcation approach. Our results
suggest that this approach allows rapid structure guided modiﬁca-
tion. Finally, molecular docking eﬀorts proved useful to explain
unexpected high potency of E-isomer 28 and suggested that the
lipophilicpocketneartheATXactivesitemaybebetterexploitedin
t h ef u t u r ef o rt h ed e s i g no fn e wi n h i b i t o r s .
’EXPERIMENTAL SECTION
Chemistry. The R and S enantiomers of building block 33 were
purchased from CSPS Pharmaceuticals, San Diego, USA. All other chemi-
calswereobtainedfromSigma-Aldrichandusedwithoutfurtherpurification
unless otherwise noted. Analytical thin layer chromatography was per-
formed on aluminum sheets precoated with silica gel 60 F254.C o l u m n
chromatography was carried out on silica gel (0.035 0.070, 90 Å, Acros).
ForisolationbycentrifugationaHeraeusMultifuge3 S-Rcentrifugewas
used. Products were spunat 4400g, at 298 K for 5 min. Nuclear magnetic
resonance spectra (
1Ha n d
13C NMR) were determined in deuterated
dimethyl sulfoxide (d6-DMSO) using a Bruker Avance 300 (
1H, 300 MHz;
13C, 75 MHz) at 298 K, unless indicated otherwise. Peak shapes are
indicated with the symbols ‘d’ (doublet), ‘dd’ (double doublet), ‘s’
(singlet), ‘bs’ (broad singlet), and ‘m’ (multiplet). Chemical shifts (δ)
are given in ppm and coupling constants J in Hz. Dimethyl sulfoxide
(δH = 2.50 ppm; δC = 39.51 ppm) was used as internal reference.
The purity of all tested compounds was determined by high-perfor-
mance liquid chromatography coupled to mass spectrometry (HPLC-
MS) and was greater than 95%. HPLC-MS measurements were per-
formed on a system equipped with a Waters 2795 Separation Module
(AllianceHT),Waters 2996 PhotodiodeArrayDetector(190 750 nm),
AtlantisT3C18column(2.1 100mm,3μm),andanLCTOrthogonal
Acceleration Time of Flight Mass Spectrometer. Samples were run at a
ﬂow rate of 0.40 mL min
 1 at 313 K, using gradient elution (water/
acetonitrile/formic acid) from 950/50/1 (v/v/v) to 50/950/1 (v/v/v).
The preparative HPLC system was equipped with a Waters 1525
BinaryHPLCPump,aWaters2487DualλAbsorbanceDetector,andan
AtlantisC18column(19 250mm,10μm).Sampleswererunataﬂow
rate of 18 mL min
 1 using gradient elution (water/acetonitrile) from
60/40 (v/v) to 10/90 (v/v).
GeneralProcedureforBorylationofAldehydesandPinacol
Deprotection(12 16).Inadryflask,bis(pinacolato)diboron(1.34g,
5.28mmol),theappropriatealdehyde(1.80mmol)andpotassiumacetate
(0.542 g, 5.52 mmol) were added to a solution ofPd(dppf)Cl2 (46.6 mg,
0.0637mmol) indimethylformamide(15mL).Thereactionmixturewas
stirred under an atmosphere of argon for 18 h at 353 K. The reaction
mixture was filtered overHyflo Super Cel medium and diluted with ethyl
acetate (100 mL). The solution was washed with brine (50 and 25 mL),
dried over magnesium sulfate, and concentrated.
The crude product was dissolved in tetrahydrofuran (11 mL) and
sodium periodate (2.22 g, 10.4 mmol) and water (2.8 mL) were added.
After stirring for 30 min, 1 M hydrochloric acid (1.1 mL) was added, and
after2h,additionalsodiumperiodate(1.17g,5.47mmol)wasaddedand
the solution was stirred for another 2 h.The reaction mixture was diluted
with ethyl acetate (20 mL) and washed with water (10 mL). The water
layer was extracted with ethyl acetate (15 mL). The combined organic
layerswerewashedwithbrine(15mL),driedovermagnesiumsulfate,and
the solution was concentrated under vacuum resulting in a light yellow
solid. The resulting product was used without further puriﬁcation.
(4-((4-Formylphenoxy)methyl)phenyl)boronic Acid (12).
Yield: 70%.
1H NMR: δ = 9.86 (s, 1H), 8.09 (s, 1H), 7.87 (d, J = 8.8,
1H),7.82(d,J=8.1,1H),7.42(d,J=8.1,1H),7.20(d,J=8.7,1H),5.24
(s, 1H).
13C NMR: δ = 191.75, 163.73, 138.49, 134.74, 132.26, 130.22,
127.15, 115.76, 70.09, 39.95 (C B(OH)2 not visible). MS: m/z
[MþH]
þ calc. 257.10, obs. 257.10.
For experimental details of compounds 13 16, see Supporting
Information.
GeneralMethodforKnoevenagelCondensation(1,17 20,
26, and E-28). To a solution of 3-(4-fluorobenzyl)thiazolidine-2,4-dione
(0.293 mmol) in ethanol (2.5 mL), piperidine (20 μL, 0.207 mmol), and
the appropriate aldehyde (0.352 mmol) were added and the solution was
refluxed for 22 h.
(Z)-4-[(4-{[3-(4-Fluorobenzyl)-2,4-dioxo-1,3-thiazolan-5-
yliden]methyl}phenoxy) methyl]benzene Boronic Acid (1).
Upon cooling the reaction mixture to room temperature, the product
precipitatedoutofsolution.Dissolvingtheproductindimethylsulfoxide
and precipitating it with 0.5 M hydrochloric acid resulted in pure
compound. Yield: 81%.
1H NMR: δ = 8.03 (s, 2H), 7.92 (s, 1H), 7.80
(d,J=8.1,2H),7.60(d,J=8.9,2H),7.41(d,J=8.0,2H),7.39 7.31(m,
J = 5.5, 8.8, 2H), 7.26 7.09 (m, J = 4.5, 8.9, 4H), 5.21 (s, 2H), 4.82 (s,
2H).
13C NMR: δ = 167.38, 165.59, 161.66 (d,
1JCF = 244), 160.33,
Figure 2. (A) Focus from inside the protein on the thiazolidine-2,4-
dionecoreofinhibitor1boundtoATX.(B)Inhibitor 1dockedintothe
active site of ATX to validate our docking approach. (C) The three best
docking poses forthe Z-isomer of28. (D) The three best docking poses
fortheE-isomerof28.Docking posesweregenerated usingthedocking
program Glide.4624 dx.doi.org/10.1021/jm200310q |J. Med. Chem. 2011, 54, 4619–4626
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138.19,134.28,133.48,132.33,131.81(d,
4JCF=3),129.95(d,
3JCF=8),
126.67, 125.55, 117.89, 115.81, 115.47 (d,
2JCF = 21), 69.52, 43.90
(C B(OH)2 not visible). MS: m/z [MþH]
þ calc. 464.11, obs. 464.19.
For experimental details of compounds 17 20, 26, and E-28 see
Supporting Information.
(4-((4-((3-(4-Fluorobenzyl)-2,4-dioxothiazolidin-5-yl)methyl)
phenoxy)methyl) phenyl)boronic Acid (21). A mixture of com-
pound 1 (50.1 mg, 0.108 mmol) and 10 wt % Pd/C (24.0 mg) in
degassedmethanol(3mL)wasstirredunderahydrogenatmospherefor
2 h. Extra 10 wt % Pd/C was added (12.0 mg) and the reaction was
allowed to continue for one night. The mixture was filtrated and
concentrated to dryness. Preparative HPLC afforded the title com-
pound. Yield:18.3 mg,77%.
1H NMR: δ=8.03 (s,2H), 7.80 (d, J=8.1,
2H),7.39(d,J=8.1,2H),7.28 6.99(m,6H),6.88(d,J=8.7,2H),5.06
(s,2H),5.00(dd,J=4.4,8.0,1H),4.60(dd,J=15.0,21.5,2H),3.14(dd,
J=8.0,14.2,1H).
13CNMR:δ=173.71,171.00,161.50(d,
1JCF=244),
157.44,138.74,134.16,131.58(d,
4JCF=3),130.56,129.66(d,
3JCF=8),
127.98, 126.52, 115.21 (d,
2JCF = 21), 114.57, 69.12, 50.94, 43.56, 35.79
(C B(OH)2 not visible). MS: m/z [MþH]
þ calc. 466.13, obs. 466.25,
[M-H2OþH]
þ calc. 448.12, obs. 448.23.
(4-((4-((3-(4-Fluorobenzyl)-4-hydroxy-2-oxothiazolidin-5-
yl)methyl)phenoxy) methyl)phenyl)boronic Acid (22). To a
solution of compound 1 (50.0 mg, 0.108 mmol) in dimethyl sulfoxide
(0.5 mL), sodium borohydride (16.3 mg, 0.430 mmol) was slowly
added. After 9 h of stirring, the reaction mixture was diluted with ethyl
acetate (4 mL) and was washed with water (2   2 mL). The organic
layer was dried over calcium chloride and concentrated in vacuo,
resulting in the title compound. Yield: 30.2 mg, 60%.
1H NMR: δ =
8.06 (s, 2H), 7.80 (d, J = 8.1, 2H), 7.39 (d, J = 8.0, 2H), 7.36   7.11 (m,
5H),6.94(d,J=8.7,2H),6.87(d,J=8.7,2H),6.71(d,J=6.2,1H),5.06
(s,2H),4.72(dd,J=7.7,15.1,1H),4.10(d,J=15.1,1H),3.67(t,J=7.9,
1H), 3.35 (s, 1H), 2.81 (dd, J = 7.3, 13.9, 1H), 2.70 (dd, J = 8.4, 13.9,
1H).
13C NMR: δ = 169.70, 161.55 (d,
1JCF = 244), 157.13, 138.85,
134.15, 133.14 (d,
4JCF = 3.0), 130.01, 130.00 (d,
3JCF = 8), 129.73,
126.54, 115.38 (d,
2JCF = 21), 114.64, 84.02, 69.11, 51.42, 44.02, 39.65.
(C B(OH)2 not visible). MS: m/z [MþH]
þ calc. 468.15, obs. 468.23.
(4-((4-((3-(4-Fluorobenzyl)-2-oxo-2,3-dihydrothiazol-5-yl)
methyl)phenoxy) methyl)phenyl)boronic Acid (23). To a
solution of compound 1 (45.7 mg, 0.0989 mmol) in dimethyl sulfoxide
(0.75 mL), sodium borohydride (29.1 mg, 0.769 mmol) was slowly
added. After 7 h of stirring the reaction mixture, concentrated sulfuric
acid(2 50μL)wasaddedovera15mininterval.Thereactionmixture
was stirred for an additional 5 h. Ethyl acetate (25 mL) was added and
the mixture was washed with water (4   10 mL). The organic layer was
dried over calcium chloride and concentrated in vacuo, affording pure
compound23.Yield:31.8mg,72%.
1HNMR:δ=8.05(s,2H),7.79(d,J=
8.1,2H),7.38(d,J=8.1,2H),7.36 7.16(m,4H),7.13(d,J=8.7,2H),
6.95 (d, J = 8.7, 2H), 6.87 (s, 1H), 5.07 (s, 2H), 4.80 (s, 2H), 3.73
(s, 2H).
13CNMR:δ = 170.43, 161.61 (d,
1JCF=244),157.13,138.85,
134.17, 133.10 (d,
4JCF = 3), 130.63, 130.63, 129.76 (d,
3JCF =8 ) ,
129.42, 126.48, 121.56, 117.78, 115.50 (d,
2JCF = 21), 114.86, 69.16,
46.78, 32.91 (C B(OH)2 not visible). MS: m/z [MþH]
þ calc. 450.13,
obs. 450.22.
3-(4-Fluorobenzyl)imidazolidine-2,4-dione (25). To a cooled
solution(273K)ofhydantoin(8.01g,80.1mmol)indimethylformamide
(140 mL) sodium hydride (60% in oil, 1.80 g, 45.0 mmol) was added. A
solution of 1-(bromomethyl)-4-fluorobenzene (5.0 mL, 41 mmol) in
dimethylformamide (5 mL) was added to the reaction mixture. The
mixture was allowed to warm upto room temperature and was stirredfor
6 h. Then, the mixture was poured into water (200 mL) and hexane
(200 mL) was added. After a night at 277 K, the precipitate was filtered
and dried to give a white solid. Yield: 4.7 g, 56%.
1H NMR: δ = 8.14 (s,
1H),7.45 7.21(m,1H),7.26 7.09(m,1H),4.51(s,2H),3.97(s,2H).
13CN M R :δ = 171.91, 161.45 (d,
1JCF = 244), 157.29, 133.04 (d,
4JCF =
3), 129.66 (d,
3JCF = 8), 115.21 (d,
2JCF = 21), 46.00, 40.29. MS: m/z
[MþH]
þ calc. 209.07, obs. 208.93.
3-(4-Fluorobenzyl)-1-methylimidazolidine-2,4-dione(27).To
a cooled solution (273 K) of 3-(4-fluorobenzyl)imidazolidine-2,4-dione
(98.1 mg, 0.471 mmol) in dimethylformamide (0.5 mL), sodium hydride
(60% in oil, 21.1 mg, 0.530 mmol) was added. Subsequently, iodomethane
(33 μL, 0.53 mmol) was added to the reaction mixture. The mixture was
a l l o w e dt ow a r mu pt or o o mt e m p e r a t u r ea n dw a ss t i r r e df o r3h .T h e n ,t h e
mixturewaspouredintoicewater(2.5mL)andhexane(2.5mL)wasadded.
After a night at 277 K, the precipitate was filtered and dried to give a white
solid. Yield: 75 mg, 72%.
1HN M R :δ =7 . 3 4  7.12 (m, 4H), 4.52 (s, 2H),
4.01 (s, 2H), 2.86 (s, 3H).
13CN M R :δ = 170.20, 161.46 (d,
1JCF = 244),
156.24, 132.92 (d,
4JCF = 3), 129.68 (d,
3JCF = 8), 115.21 (d,
2JCF = 21),
51.36, 40.74, 29.21. MS: m/z [MþH]
þ calc. 223.09, obs. 223.06.
(Z)-(4-((4-((1-(4-Fluorobenzyl)-3-methyl-2,5-dioxoimidazoli-
din-4-ylidene)methyl) phenoxy)methyl)phenyl)boronic Acid
(Z-28). To a cooled solution (273 K) of hydantoine 26 (10.1 mg,
0.0224mmol)andsodiumhydride(60%inoil,1.46mg,0.0365mmol)in
DMF (0.15 mL), iodomethane (2.25 μL, 0.0361 mmol) was added. The
mixturewasallowedtowarmuptoroomtemperatureandwasstirredfor4
h.FinalproductwasisolatedbyusingpreparativeHPLC.Z-configuration
confirmedbythechemicalshiftofthevinylandmethylprotonreportedin
literature.
23
Yield:6.97mg,68%.
1HNMR:δ=8.11(s,1H),7.80(d,J=8.1,2H),
7.50 7.30 (m, 6H), 7.26 7.10 (m, 2H), 7.05 (d, J = 8.8, 2H), 6.76 (s,
1H), 5.14 (s, 2H), 4.67 (s, 2H), 2.92 (s, 3H).
13C NMR: δ = 163.01,
159.92, 156.78 (d,
1JCF = 249), 138.52, 134.19, 132.55 (d,
4JCF = 3),
131.28, 129.75 (d,
3JCF = 8), 128.50, 126.58, 124.66, 115.31 (d,
2JCF =
21), 114.55, 111.56, 69.30, 41.12, 30.35 (C B(OH)2 not visible). MS:
m/z [MþH]
þ calc. 461.17, obs. 461.12.
(E)-(4-((4-((2,5-Dioxopyrrolidin-3-ylidene)methyl)phenoxy)
methyl)phenyl)boronicAcid(31).Toaheated(343K)solutionof
compound30(159mg,0.442mmol)
16inmethanol(5mL)aldehyde12
(106 mg, 0.414 mmol) was added. After 1 h of heating, the reaction
mixture was cooled using an ice bath resulting in precipitation of the title
compound. The precipitate was filtered and washed with ice-cold
methanol resulting in compound 31. Yield: 88 mg, 63%.
1HN M R :δ =
11.34(s,1H),8.04(s,2H),7.80(d,J=8.0,2H),7.57(d,J=8.9,2H),7.41
(d, J = 8.0, 2H), 7.33 (t,
4J = 2.1, 1H), 7.10 (d, J = 8.8, 2H), 5.19 (s, 2H),
3.60 (d,
4J =2 . 2 ,2 H ) .
13CN M R :δ = 175.80, 172.09, 159.47, 138.42,
134.22, 132.00, 131.31, 126.96, 126.54, 124.16, 115.31, 69.31, 34.71
(C B(OH)2 not visible). MS: m/z [MþH]
þ calc. 338.12, obs. 338.11.
(E)-(4-((4-((1-(4-Fluorobenzyl)-2,5-dioxopyrrolidin-3-ylidene)
methyl)phenoxy) methyl)phenyl)boronic Acid (32). To a
solution ofcompound 31(30mg,0.0890 mmol) in dimethylformamide
(0.3 mL) sodium hydride (60% in oil, 3.65 mg, 0.0913 mmol) was
added. After addition of 4-fluorobenzyl bromide (24 μL, 0.19 mmol),
thereactionmixturewasstirredfor4h.Inaddition,potassiumcarbonate
(2.04 mg,0.0148 mmol) was added andthe reaction mixturewas stirred
overnight. Then, the mixture was poured into ice water (0.9 mL) and
hexane (0.3 mL) was added. After a night at 277 K, the precipitate was
filtered,dried,andpurifiedusingpreparativeHPLCtogiveawhitesolid.
E-Configuration confirmed by the chemical shift of the vinyl proton
reported in literature.
16 Yield: 13 mg, 32%.
1H NMR: δ = 8.04 (s, 2H),
7.80 (d, J =8.1, 2H), 7.61 (d, J= 8.9, 2H),7.45 (t,
4J = 2.1, 1H), 7.41 (d,
J=8.0,2H),7.38 7.29(m,2H),7.23 7.04(m,4H),5.19(s,2H),4.66
(s,2H),3.74(d,
4J=2.1,2H).
13CNMR:δ=174.19,170.59,161.44 (d,
1JCF=244),159.65,138.39,134.22,132.59(d,
4JCF=3),132.31,132.17,
129.73 (d,
3JCF = 8), 126.85, 126.54, 122.27, 115.36, 115.22 (d,
2JCF =
21), 69.33, 40.71, 33.74 (C B(OH)2 not visible). MS: m/z [MþH]
þ
calc. 446.16, obs. 446.12.
(S)-2-(4-Fluorobenzyl)-7-hydroxy-10,10a-dihydroimidazo-
[1,5-b]isoquinoline-1,3(2H,5H)-dione (S-34). Compound S-33
(100 mg, 0.518 mmol) was dissolved in a mixture of dioxane and water4625 dx.doi.org/10.1021/jm200310q |J. Med. Chem. 2011, 54, 4619–4626
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(3:1,4mL)and30wt%ofsodiumhydroxidesolutionwasusedtoadjust
the pH to 14. The reaction mixture was heated to 313 K and 4-fluoro-
benzyl isocyanate (100 μL, 0.785 mmol) was added. After 2 h of stirring,
the mixture was cooled to room temperature and the resulting solid was
removed using centrifugation. From the resulting solution, dioxane was
evaporatedandconcentratedhydrochloricacidwasusedtoadjustthepH
to 1. After refluxing the reaction mixture for 2 h 30 min, it was cooled to
278 K affording a white precipitate. Washing the precipitate with ice-cold
water (3   1 mL) afforded pure compound S-34. Yield: 30 mg, 18%.
1H
NMR:δ=9.37(s,1H),7.35 7.30(m,2H),7.18 7.12(m,2H),7.06 7.03
(m, 1H), 6.65 6.63 (m, 2H), 4.77 (d, J = 16.8, 1H), 4.58 (s, 2H), 4.32 
4.27 (m, 2H), 3.05 (m, 1H), 2.82 2.64 (m, 1H).
13CN M R :δ = 172.76,
161.44 (d,
1JCF = 244), 156.07, 154.60, 132.82 (d,
4JCF = 3), 132.35, 130.13,
129.51 (d,
3JCF = 8), 121.45, 115.26 (d,
2JCF = 21), 114.30, 112.67, 54.54,
41.23, 40.56, 29.02. MS: m/z [MþH]
þ calc. 327.11, obs. 327.09.
(R)-2-(4-Fluorobenzyl)-7-hydroxy-10,10a-dihydroimidazo-
[1,5-b]isoquinoline-1,3(2H,5H)-dione (R-34). For reaction de-
tails, see compound S-34. Yield: 29%.
1HN M R ,
13C NMR, and MS,
see Supporting Information.
(S)-(4-(((2-(4-Fluorobenzyl)-1,3-dioxo-1,2,3,5,10,10a-hexa-
hydroimidazo[1,5-b]isoquinolin-7-yl)oxy)methyl)phenyl)boronic
Acid(S-35).Toaheatedsolution(323K)ofcompoundS-34(15.3mg,
0.0469 mmol) in acetone (0.3 mL), potassium carbonate (10.2 mg,
0.0738 mmol) and 4-(bromomethyl)phenylboronic acid (12.4 mg,
0.0577 mmol) were added. After 4 h of stirring and heating, additional
potassium carbonate (10.1 mg, 0.0730 mmol) was added and the
suspension was stirred overnight. Finally, the reaction mixture was
diluted with ethyl acetate and the organic layer was washed with 1 M
hydrochloric acid (2   0.5 mL) and brine (0.5 mL), dried over sodium
sulfate, and concentrated in vacuo. The resulting solid was further
purified using preparative HPLC affording pure compound S-35. Yield:
11mg,52%.
1HNMR:δ=8.06(s,2H),7.78(d,J=8.1,2H),7.50 7.27
(m, 4H), 7.27 7.05 (m, 3H), 7.02 6.76 (m, 2H), 5.09 (s, 2H), 4.82
(d, J = 17.0, 1H), 4.58 (s, 2H), 4.42 4.20 (m, 2H), 3.19 3.02
(m, 1H), 2.80 2.71 (m, 1H).
13C NMR: δ = 172.72, 161.46 (d,
1JCF
= 244), 157.09, 154.60, 138.74, 134.17, 132.81 (d,
4JCF = 3), 132.60,
130.23, 129.55 (d,
3JCF = 8), 126.49, 123.60, 115.28 (d,
2JCF = 21),
113.87, 112.47, 69.20, 54.40, 41.30, 40.60, 29.00 (C B(OH)2 not
visible). MS: m/z [MþH]
þ calc. 461.17, obs. 461.14.
(R)-(4-(((2-(4-Fluorobenzyl)-1,3-dioxo-1,2,3,5,10,10a-hexa-
hydroimidazo[1,5-b]isoquinolin-7-yl)oxy)methyl)phenyl)-
boronic acid (R-35). For reaction details, see compound S-35. Yield:
56%.
1H NMR,
13C NMR, and MS, see Supporting Information.
Choline Release Assay.
13 Measuring ATX activity using LPC
(18:1) as substrate was determined as follows. In an opaque flat-bottom
96-wellsplate(Greiner)wasadded0.5μLdimethylsulfoxidecontaining
inhibitor, to 25 μL recombinant ATX (∼20 nM) in Tris-HCl buffer
(0.01% Triton X-100 and 50 mM Tris-HCl, pH 7.4). Finally, 25 μLo f
80 μM LPC (18:1) in Tris-HCl buffer (10 mM MgCl2, 10 mM CaCl2,
0.01% Triton X-100 and 50 mM Tris-HCl, pH 7.4) was added to each
well and the plate was incubated at 310 K. The above-described mixture
with dimethyl sulfoxide alone was used as a control. LPC without ATX
was taken as control for autohydrolysis of LPC. For each inhibitor, ten
concentrations were measured covering a range of 0.01 to 30 μMt o
determineIC50values.After4hofincubation,50μLABTS(2mM)and
horseradish peroxidase (5 U mL
 1) was added to the reaction mixture
and absorbance was measured and used to correct for absorbance of
the molecules. Finally, 50 μL choline oxidase (5 U mL
 1) in Tris-HCl
(0.01% Triton X-100 and 50 mM Tris-HCl, pH 7.4) was added for
colorimetric reaction. Absorbance was measured in a Perkin-Elmer
Envisionplatereader(λ=405nm).DatawereanalyzedusingGraphpad
Prism software.
In addition, the eﬀect of the inhibitors on the enzymatic coloring
reaction was investigated using 40 μM choline at 30 μM inhibitor using
the above-described coloring reagents. The enzymatic coloring reaction
was not eﬀected by the inhibitors.
Docking Experiments, Protein, and Ligand Preparation.
The X-ray structure of ATX in complex with inhibitor 1 (PDB ID:
2XRG) was used for the docking studies. The protein structure was
prepared using the Schr€ odinger Suite 2010 Protein Preparation Wizard
(withEpik2.1,
24Impact5.6,andPrime2.2).Theinitial3Dstructuresof
the ligands were generated using LigPrep 2.4 and the ligand partial
charges were ascribed using the OPLS2005 force-field as performed by
Glide 5.6.
20 22 We defined the binding region by a 20 Å   20 Å   20 Å
box centered on the central position of inhibitor 1 in the crystal ATX
complex.Weusedpositionalconstraintsforthetwooxygenatomsofthe
boronic acid and the arylic carbon direct next to the boron atom in
inhibitor1.TheGlideEmodelscorewasusedtorankthedockingposes.
Pictures were made using PyMOL 1.3.
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